<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Mon, 09 Nov 2009 09:03:05 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Biostar Raises $3.6 Million</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</guid>
      <description><![CDATA[Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614366>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 17:26:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSPM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</link>
    </item>
    <item>
      <title>Bulls Back On Track?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</guid>
      <description><![CDATA[Good morning. With chants of &quot;Dow 10K… Dow 10K&quot; once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614255>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 16:21:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</link>
    </item>
    <item>
      <title>Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</guid>
      <description><![CDATA[Ford's 2,215 page 2007 master contract with the UAW 
1941 UAW-Ford contract<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614051>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 13:52:50 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">F</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</link>
    </item>
    <item>
      <title>King Beats, But Earnings Down</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611947</guid>
      <description><![CDATA[King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611947>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 20:08:54 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ALO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">OMRI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PTIE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ZGEN</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611947</link>
    </item>
    <item>
      <title>Your Kind of Day?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</guid>
      <description><![CDATA[As a rule, I try not to read too terribly much into a &quot;Fed Day&quot; as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on &quot;Fed Days.&quot; But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611831>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 19:06:48 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</link>
    </item>
    <item>
      <title>The Dollar-Proof Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</guid>
      <description><![CDATA[Don't put off this important piece of the financial-planning process.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611744>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 17:31:14 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GLD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IEO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MON</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STPZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UDN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VEU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VSS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WIP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</link>
    </item>
    <item>
      <title>MFI Stock Review:  Cephalon (CEPH)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3610517</guid>
      <description><![CDATA[Cephalon has three drugs with good growth potential. If sales develop according to the company's plan, the current price will prove to be a bargain.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3610517>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 16:56:11 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3610517</link>
    </item>
    <item>
      <title>What Investors Should Look for In Today’s Fed Statement</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</guid>
      <description><![CDATA[In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605772>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 13:04:24 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BCS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ING</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</link>
    </item>
    <item>
      <title>Are Discount Brokers Shares Worth Owning?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</guid>
      <description><![CDATA[The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&amp;P gain 15%.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604683>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 01:28:03 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMTD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ETFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SCHB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</link>
    </item>
    <item>
      <title>Technology Rises And Buying Facebook</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</guid>
      <description><![CDATA[Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%.&#160;&#160; Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601987>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 16:54:11 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EBAY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</link>
    </item>
    <item>
      <title>Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3613879</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Nov. 6--Targacept Inc. posted its first quarterly profit in nearly three years yesterday, bolstered in large part by a $10 million milestone payment by AstraZeneca PLC. &lt;/li&gt;&lt;li&gt;Targacept, based in Piedmont Triad Research Park in Winston-Salem, is developing drugs based on nicotine research to treat diseases of the central nervous system. &lt;/li&gt;&lt;li&gt;The payment was the result of Targacept's research in adult attention deficit/hyperactivity disorder involving its AZD3480 drug compound, also known as TC-1734.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3613879>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TRGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3613879</link>
    </item>
    <item>
      <title>Corrections Corp. of America 3Q profit jumps</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3608434</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;NASHVILLE, Tenn. - Prison operator Corrections Corp. of America said its third-quarter profit jumped 19 percent as more prisoners were locked up in its California and Arizona facilities.&lt;/li&gt;&lt;li&gt;That was up from $37.9 million, or 30 cents per share, during the same period last year.&lt;/li&gt;&lt;li&gt;Not counting an unusual tax benefit, the company would have earned 33 cents per share - above the 31 cents per share average expected by analysts surveyed by Thomson Reuters.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3608434>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 23:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CXW</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3608434</link>
    </item>
    <item>
      <title>Auditor: Canada disaster planning is poor</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3607165</guid>
      <description><![CDATA[Auditor: Canada disaster planning is poor<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3607165>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 15:07:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3607165</link>
    </item>
    <item>
      <title>Vaccine-short Canada exporting 'surplus'</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3607404</guid>
      <description><![CDATA[Vaccine-short Canada exporting 'surplus'<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3607404>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 12:06:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3607404</link>
    </item>
    <item>
      <title>Largest malaria vaccine trial under way</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3602457</guid>
      <description><![CDATA[Largest malaria vaccine trial under way<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3602457>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 15:03:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3602457</link>
    </item>
    <item>
      <title>Canada's H1N1 flu vaccine running short</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3594381</guid>
      <description><![CDATA[Canada's H1N1 flu vaccine running short<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3594381>[More...]</a>]]></description>
      <pubDate>Fri, 30 Oct 2009 12:24:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3594381</link>
    </item>
    <item>
      <title>GlaxoSmithKline third quarter profit up 11 percent</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3586499</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;LONDON - GlaxoSmithKline PLC, the world's second largest drug maker by revenue, posted Wednesday an 11 percent rise in third quarter earnings on the back of strong sales of the flu drug Relenza and forecast an even bigger boost from its swine flu vaccines in the final quarter of the year.&lt;/li&gt;&lt;li&gt;London-based Glaxo reported net profit of 1.44 billion pounds ($2.35 billion) for the three months to Sept. 30, compared to 1.29 billion pounds a year ago.&lt;/li&gt;&lt;li&gt;Glaxo, which has been hit by rising competition from generic versions of its previously patented drugs, is expected to receive an earnings windfall from products dashed out in response to the H1N1 flu virus.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3586499>[More...]</a>]]></description>
      <pubDate>Wed, 28 Oct 2009 13:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3586499</link>
    </item>
    <item>
      <title>Biotech firm Cephalon 3Q profit falls 2.7 percent</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3584934</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;FRAZER, Pa. - Cephalon Inc. on Tuesday said third-quarter earnings fell from a year ago, when the biotech firm recorded a $66.1 million tax benefit.&lt;/li&gt;&lt;li&gt;Cephalon posted a net income of $102.7 million, or $1.31 per share, compared with $105.6 million, or $1.34, in the same period a year ago.&lt;/li&gt;&lt;li&gt;But Cephalon's adjusted earnings exceeded their average forecast of $1.41 per share.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3584934>[More...]</a>]]></description>
      <pubDate>Tue, 27 Oct 2009 22:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3584934</link>
    </item>
    <item>
      <title>FDA OK's new leukemia treatment</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3582472</guid>
      <description><![CDATA[FDA OK's new leukemia treatment<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3582472>[More...]</a>]]></description>
      <pubDate>Tue, 27 Oct 2009 11:18:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3582472</link>
    </item>
    <item>
      <title>Evening Standard, London, Market Report Column</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3576618</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Oct. 23--Shares on the London stock market soared while the pound slumped  against the dollar as the UK economy continued to reel against the worst  recession on record. &lt;/li&gt;&lt;li&gt;That was the conclusion of financial markets on learning the shock news  that the UK economy continued shrinking during the third quarter. &lt;/li&gt;&lt;li&gt;The move may confound the man in the street, but dealers say the  Government will now have to continue with its quantitative easing programme  and much of that money will find its way back into the stock market as  investors look for better returns.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3576618>[More...]</a>]]></description>
      <pubDate>Fri, 23 Oct 2009 23:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AAUK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BHP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">KAZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NWS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VOD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3576618</link>
    </item>
    <item>
      <title>RidgewaterEquity.Com Free Fundamental Sector &amp;Amp; Market Research on BQI, TS, SLT, COL, TMX and RYL</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3597152</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;RidgewaterEquity.com inspires to bring the best from the internet under one roof, providing you with a one click option to view what the market, researchers and financial pundits worldwide have to say about any particular large cap stocks in any given financial environment. &lt;/li&gt;&lt;li&gt;Once you sign up as a free member you will have free unlimited access to all our reports, research tools and more.&lt;/li&gt;&lt;li&gt;We have recently begun in-depth analysis of the following equities &amp;amp; their respective sectors:&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3597152>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 10:01:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BQI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">COL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SLT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TMX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3597152</link>
    </item>
    <item>
      <title>Procter &amp;Amp; Gamble Co. Up 13% Since Added to Galtstock Long Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3576305</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Subscribers to galtstock.com &quot;Long-Term Portfolio&quot; service (membership) invest in solid long-term holdings. &lt;/li&gt;&lt;li&gt;Other stocks in our portfolio are Procter &amp;amp; Gamble (NYSE: PG), Coca-Cola (NYSE: KO), GlaxoSmithKline (NYSE: GSK), and McDonald's Corp. (NYSE: MCD).&lt;/li&gt;&lt;li&gt;To sign up for Galt's Long-Term Portfolio service, please visit the website at http://www.galtstock.com/Long-Term-Portfolio.html with secure check out.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3576305>[More...]</a>]]></description>
      <pubDate>Fri, 23 Oct 2009 21:07:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">KO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MCD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PG</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3576305</link>
    </item>
    <item>
      <title>Eurand Announces Pricing of Offering of Ordinary Shares</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3571713</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the pricing of its previously disclosed public offering of 8,500,000 ordinary shares at an initial price to the public of $11.25 per share. &lt;/li&gt;&lt;li&gt;The shares are being offered through an underwriting syndicate led by Deutsche Bank Securities and BofA Merrill Lynch, together with co-managers Cowen and Company and Thomas Weisel Partners.  &lt;/li&gt;&lt;li&gt;Of the 8,500,000 shares being offered, 2,000,000 are newly issued by Eurand N.V., and the remaining 6,500,000 are currently issued and outstanding.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3571713>[More...]</a>]]></description>
      <pubDate>Thu, 22 Oct 2009 13:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">EURX</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3571713</link>
    </item>
    <item>
      <title>Cubist Pharmaceuticals 3rd Quarter Total Net Revenues Up 28%</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3555150</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for   the third quarter ended September 30, 2009.&lt;/li&gt;&lt;li&gt;With three quarters of 2009 revenue recorded, Cubist has tightened its   full year 2009 guidance for CUBICIN U.S. net revenue to between $520 and   $525 Million, which is within the range the company announced in   January. &lt;/li&gt;&lt;li&gt;Our strong top and bottom line results have   been achieved in an environment that has been tough for many branded   pharmaceuticals.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3555150>[More...]</a>]]></description>
      <pubDate>Thu, 15 Oct 2009 20:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">AZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CBST</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3555150</link>
    </item>
    <item>
      <title>HCP to Report Third Quarter 2009 Financial Results and Host Conference Call/Webcast</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3533092</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;HCP (NYSE:HCP) will report its third quarter financial results on   Tuesday, November 3, 2009, before the open of trading on the New York   Stock Exchange. &lt;/li&gt;&lt;li&gt;The Company will also host a conference call and webcast   at 9 a.m. Pacific Time (12 noon Eastern Time) that same day in order to   review its financial performance and operating results for the quarter   ended September 30, 2009.&lt;/li&gt;&lt;li&gt;The dial-in number for the conference call is (800) 706-7748 (U.S.) or   (617) 614-3473 (International).&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3533092>[More...]</a>]]></description>
      <pubDate>Tue, 06 Oct 2009 20:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HCP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3533092</link>
    </item>
    <item>
      <title>Ingenico Announces the Acquisition of Easycash, a Leading Payment Services Provider Based in Germany</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3505572</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Ingenico announces the acquisition of easycash, a leading payment services provider based in Germany&lt;/li&gt;&lt;li&gt;Ingenico (ISIN : FR0000125346 - Euronext Paris : ING) announces today the acquisition of 100% of easycash Beteiligungen GmbH, a leading German payment services provider for an enterprise value of EUR 290 million.&lt;/li&gt;&lt;li&gt;This transaction is a major step in Ingenico's plan to position itself in the transaction services value chain in order to offer solutions around POS terminals and to leverage on the growth of payment transactions in the coming years.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3505572>[More...]</a>]]></description>
      <pubDate>Fri, 25 Sep 2009 07:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">EURX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NSR</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NUAN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WNS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3505572</link>
    </item>
    <item>
      <title>Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics in Oncology</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3466615</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi   therapeutics company, announced today that the European Patent Office   (EPO) has issued a notification of intent to grant for a patent in the   Kreutzer-Limmer III patent series (EP Application No 02702247.4). &lt;/li&gt;&lt;li&gt;The   Kreutzer-Limmer III patent series extends the scope and breadth of   Alnylam's fundamental intellectual property estate that comprises   numerous issued or granted patents and a large number of pending patent   applications that together broadly cover RNAi therapeutics, including   small interfering RNAs, or siRNAs, the molecules that mediate RNAi.&lt;/li&gt;&lt;li&gt;&quot;We are pleased with the EPO's decision to grant claims from   Kreutzer-Limmer III, an early filed patent in RNAi therapeutics research   that described many applications for siRNAs and their use in oncology   indications,&quot; said Barry Greene, President and Chief Operating Officer   of Alnylam Pharmaceuticals.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3466615>[More...]</a>]]></description>
      <pubDate>Wed, 09 Sep 2009 11:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ALNY</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3466615</link>
    </item>
    <item>
      <title>Pronova BioPharma Receives 2009 Frost &amp;Amp; Sullivan Award for Excellence in Financial &amp;Amp; Risk Management</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3463623</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;8 September 2009, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) (&quot;Pronova BioPharma&quot; or &quot;the company&quot;) today announces that it has been awarded the 2009 Frost &amp;amp; Sullivan Excellence in Financial &amp;amp; Risk Management Award in the Global Heart Health Ingredients market for its lead product Omacor(R)/LovazaTM, the first and only EU- and FDA-approved omega-3 derived prescription drug.&lt;/li&gt;&lt;li&gt;The Frost &amp;amp; Sullivan Excellence in Financial &amp;amp; Risk Management Awards are presented annually to companies that demonstrate outstanding management of current market conditions, besides preparing for the future, above others within their respective industries.  &lt;/li&gt;&lt;li&gt;This award recognises Pronova BioPharma's excellent product quality and favourable customer opinions, continued strong customer demand for Omacor/Lovaza, innovation supporting next generation omega-3 derived products (through ongoing collaborations in indications such as heart failure, atrial fibrillation and cardiac disease in type II diabetic patients) and sound operational and financial risk management practices.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3463623>[More...]</a>]]></description>
      <pubDate>Tue, 08 Sep 2009 15:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3463623</link>
    </item>
    <item>
      <title>Frost &amp; Sullivan Global Heart Health Ingredients Excellence in Financial &amp; Risk Management Award Conferred on Pronova BioPharma</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3463175</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;LONDON, Sept. 8 /PRNewswire/ -- The 2009 Frost &amp; Sullivan Global Heart Health Ingredients Excellence in Financial &amp; Risk Management Award is presented to Pronova BioPharma ASA. &lt;/li&gt;&lt;li&gt;Pronova BioPharma has demonstrated excellence in financial management. &lt;/li&gt;&lt;li&gt;Pronova BioPharma's return on assets (ROA) improved from 16.8 per cent in 2007 to 34.5 per cent in 2008.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3463175>[More...]</a>]]></description>
      <pubDate>Tue, 08 Sep 2009 11:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3463175</link>
    </item>
    <item>
      <title>HCP Announces Jury Verdict in Ventas Litigation</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3459564</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;HCP (NYSE:HCP) announced that a jury reached a verdict in favor of   Ventas, Inc., in an action brought against HCP in the United States   District Court for the Western District of Kentucky for tortious   interference with prospective business advantage in connection with   Ventas's 2007 acquisition of Sunrise Senior Living REIT. &lt;/li&gt;&lt;li&gt;The jury   awarded Ventas approximately $101 million in compensatory damages.   &lt;/li&gt;&lt;li&gt;During the trial, the court dismissed Ventas's claims for punitive   damages.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3459564>[More...]</a>]]></description>
      <pubDate>Fri, 04 Sep 2009 16:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HCP</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VTR</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3459564</link>
    </item>
    <item>
      <title>Form  4          RHEIN PETER L             For: Nov 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604138</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604138>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 22:09:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HCP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604138</link>
    </item>
    <item>
      <title>Form  4          FANNING ROBERT R JR       For: Nov 01 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599857</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599857>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:51:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HCP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599857</link>
    </item>
    <item>
      <title>Form  4          RYLAND GROUP INC          For: Nov 02  Filed by: METCALFE NORMAN J (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599852</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599852>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599852</link>
    </item>
    <item>
      <title>Form  4          MANSOUR NED               For: Nov 02 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599821</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599821>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:44:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599821</link>
    </item>
    <item>
      <title>Form  4          VAN SCHOONENBERG ROBERT   For: Nov 02 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599814</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599814>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:36:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599814</link>
    </item>
    <item>
      <title>Form  4          RYLAND GROUP INC          For: Nov 02  Filed by: ST MARTIN CHARLOTTE (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599796</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599796>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:31:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599796</link>
    </item>
    <item>
      <title>Form  4          MELLOR ROBERT E           For: Nov 02 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599790</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599790>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:26:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599790</link>
    </item>
    <item>
      <title>Form  4          RYLAND GROUP INC          For: Nov 02  Filed by: JEWS WILLIAM L (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599782</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599782>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:22:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599782</link>
    </item>
    <item>
      <title>Form  4          HERNANDEZ ROLAND A        For: Nov 02 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599772</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599772>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:16:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599772</link>
    </item>
    <item>
      <title>Form  4          RYLAND GROUP INC          For: Nov 02  Filed by: FRECON LESLIE M (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3599751</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3599751>[More...]</a>]]></description>
      <pubDate>Mon, 02 Nov 2009 22:10:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">RYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3599751</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=ALNY,CEPH,CXW,EURX,GSK,HCP,RYL," rel="self" type="application/rss+xml" />
  </channel>
</rss>